ASLAN Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ASLAN Pharmaceuticals Limited generated cash of -$46,359,842, which is less than the previous year. Cash used in financing activities reached the amount of $10,720,456 last year. Net change in cash is therefore -$35,650,019.
Cash Flow
| 2014 | -6.28M | -32.73K | 12.09M |
|---|---|---|---|
| 2015 | -11.05M | -40.06K | 32.62M |
| 2016 | -5.56M | -520.73K | 31.40M |
| 2017 | -35.10M | -331.24K | 33.80M |
| 2018 | -39.46M | -23.09M | 40.89M |
| 2019 | -25.80M | 5.38K | 19.09M |
| 2020 | -15.05M | 927 | 7.17M |
| 2021 | -33.99M | -28.15K | 109.86M |
| 2022 | -38.40M | 414.69K | 4.72M |
| 2023 | -46.35M | -10.63K | 10.72M |
ASLN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 56.90M | 90.16M | 14.32M | 22.20M | 28.90M | 50.57M | 56.39M | 27.40M | 5.22M | 9 |
Operating activities | ||||||||||
Net income | -44.21M | -51.28M | -31.59M | -16.97M | -46.65M | -42.17M | -40.71M | -9.00M | -13.32M | -7.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 348.49K | 331.75K | 282.22K | 297.75K | 445.35K | 241.76K | 214.30K | 75.49K | 48.90K | 24.85K |
Stock-based compensation expense | 2.70M | 1.97M | 2.19M | 345.83K | 43.78K | 0 | 1.14M | 1.41M | 1.41M | 532.74K |
| Deferred income tax benefit | 2.70M | 1.97M | 2.19M | 345.83K | 43.78K | 0 | 1.14M | 1.41M | 1.41M | 532.74K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | -528.84K | 0 | 0 | 1.41M | -1.28M | 0 | 0 |
Inventories | 0 | 0 | 0 | 528.84K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -4.86M | 9.66M | 797.22K | 447.71K | -3.44M | 1.41M | 1.41M | 2.11M | -597.90K | 434.55K |
Cash generated by operating activities | -46.35M | -38.40M | -33.99M | -15.05M | -25.80M | -39.46M | -35.10M | -5.56M | -11.05M | -6.28M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -16.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -10.78K | -27.11K | -48.80K | -5.05K | -2.99K | -23.08M | -306.44K | -454.02K | -32.37K | -33.24K |
Acquisitions Net | 148 | 1.17K | 0 | 1.21K | 2.48M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -10.63K | 414.69K | -28.15K | 927 | 5.38K | -23.09M | -331.24K | -520.73K | -40.06K | -32.73K |
Financing activities | ||||||||||
Common Stock Issued | 23.02M | 0 | 101.55M | 7.64M | 14.73M | 42.18M | 33.57M | 22.35M | 33.18M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -8.13M | -202.60K | 0 | 0 | 0 | -364.48K | 0 | 0 |
Cash used in financing activities | 10.72M | 4.72M | 109.86M | 7.17M | 19.09M | 40.89M | 33.80M | 31.40M | 32.62M | 12.09M |
Net Change In Cash | -35.65M | -33.26M | 75.84M | -7.87M | -6.70M | -21.66M | -5.86M | 24.15M | 21.08M | 5.57M |
Cash at end of period | 21.25M | 56.90M | 90.16M | 14.32M | 22.20M | 28.90M | 50.52M | 51.55M | 26.30M | 5.57M |
| Data source | Data source | Data source | Data source | Data source | Data source |